Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that adding platelet-rich plasma to 5% minoxidil treatment improved hair growth outcomes in patients with androgenetic alopecia compared to minoxidil alone.

This study found that combining minoxidil with platelet-rich plasma and basic fibroblast growth factor was the most effective treatment for increasing hair density in androgenetic alopecia, showing a significant improvement over minoxidil alone.

Minoxidil, when applied to the scalp, can stimulate hair growth but effects vary, stop if treatment ends, and it may cause side effects like fluid retention.

In AGA mouse models, this study found that the combination of nickel–copper nanozymes and minoxidil in dissolvable microneedles significantly enhanced hair regeneration and improved the hair follicle microenvironment by reducing reactive oxygen species and increasing vascular density, compared to minoxidil alone.

This study found that microneedling combined with 5% minoxidil significantly improved hair growth in patients with androgenetic alopecia compared to using 5% minoxidil alone, with headache and erythema being common side effects in both groups.

This study reported that CoFe2O4 magnetic nanoparticles efficiently catalyzed the synthesis of minoxidil from 2,6-diamino-4-chloro-pyrimidine N-oxide, achieving a 95% yield with sustained reusability.

In this study using diabetic rat models, the combination of AMD3100 and low-dose FK506 reduced wound healing time and improved microcirculation in diabetic foot ulcers, indicating a promising new systemic therapy.

This study optimized a screening assay to identify molecules that inhibit or enhance TRPM5 ion channel activity, which may have implications for treating dysfunctions linked to cardiac arrhythmias and diabetes.

Minoxidil helps 32% of patients with hereditary baldness regrow hair.

This case report describes a possible association between topical 5% minoxidil use and inferior hemiretinal artery occlusion in a 21-year-old Asian Indian male with androgenic alopecia.

In this study, maslinic acid applied topically was observed to stimulate hair growth in mice comparably to minoxidil, primarily activating pathways like Wnt/β-catenin, and suggesting a link between hair growth and cilia activity.

This study suggests that neither autologous platelet-rich plasma nor 5% topical minoxidil reliably outperforms the other as a monotherapy for male androgenetic alopecia, with combination therapy often showing superior outcomes.

This pilot study found that among male androgenetic alopecia patients, 2.5 mg oral minoxidil with platelet-rich plasma led to higher patient satisfaction than 1.25 mg, though hair count improvements were not statistically significant.

In this randomized clinical trial, minoxidil at 5 mg was not found to be superior to 2.5 mg for treating male androgenetic alopecia over 24 weeks, though the higher dose more frequently caused side effects like pre-tibial edema and dizziness.

This study reported that combined oral finasteride and topical 5% minoxidil treatment in men with male-pattern hair loss improved hair growth by initiating anagen in pre-existing but deficient follicles, yet the growth rates remained unchanged and did not normalize hair productivity.

Minoxidil is used to treat hair loss.

This study observed that minoxidil significantly downregulated 5α-R2 gene expression in human keratinocyte cells, suggesting an antiandrogenic mechanism of action in alopecia.

Low-dose oral minoxidil does not cause tachycardia in hair loss patients.

This study found that systemic treatment with DS77754007, a KLK5 inhibitor, improved skin symptoms in a mouse model of Netherton Syndrome more effectively than certain antibody treatments, suggesting KLK5 inhibition as a promising therapeutic approach for this condition.

This study reports the purification of a specific sulphotransferase from rat liver that catalyzes the sulphation of minoxidil, potentially implicating it in minoxidil's bioactivation.

Spironolactone helps prevent swelling caused by minoxidil in women with hair loss.

This study highlights a treatment approach using dissolving microneedle patches containing nanomicelles formed by stevioside to enhance the therapeutic efficacy and safety of poorly soluble drugs, as depicted in the cover illustration with luxuriant hair symbolizing its potential effectiveness.

This study compared the effectiveness and safety of microneedling with PRP versus minoxidil and finasteride topical therapy in adult males with androgenetic alopecia, finding similar hair density improvements in both groups, though microneedling with PRP had a quicker onset of action.

This study found no significant association between mineralocorticoid receptor antagonist therapy and mortality in patients with SARS-CoV-2 infection.

This study found that adding a SULT1A1 enzyme booster to minoxidil treatment improved hair growth response in 65% of androgenetic alopecia patients who were previous non-responders to minoxidil alone, with females benefiting more than males.

Minoxidil may improve nail growth and appearance.

No specific results are reported in this abstract, but it mentions that minoxidil is mainly used for hypertension that does not respond to other treatments due to side effects like tachycardia, fluid retention, and hypertrichosis.

This study reported that oral minoxidil was associated with clinical improvement in androgenetic alopecia and telogen effluvium, showing better outcomes compared to controls.

Human stem cells can aid stroke recovery, research experiences boost students' career aspirations, minoxidil may reduce cancer spread, a molecule can slow tumor growth, a protein affects water flow in cells, magnesium behaves differently at tiny scales, and a new method detects slow-moving objects.